Vimarsana
Biggest News Aggregation in the World

Page 2 - Sharing Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sharing Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sharing Statement Today - Breaking & Trending Today

Early Metformin in Gestational Diabetes - Vimarsana News

Early Metformin in Gestational Diabetes

This randomized clinical trial compares use of metformin vs placebo in treating the maternal and neonatal outcomes associated with gestational diabetes.

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial | Cardiology | JAMA - Vimarsana News

Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial | Cardiology | JAMA

This phase 1 randomized clinical trial evaluates the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamic biomarker effects of muvalaplin in

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial | Dementia and Cognitive Impairment | JAMA - Vimarsana News

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial | Dementia and Cognitive Impairment | JAMA

This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patie

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial | Coronavirus (COVID-19) | JAMA - Vimarsana News

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial | Coronavirus (COVID-19) | JAMA

This randomized clinical trial compares the effects of 3 doses of bamlanivimab monotherapy (700 vs 2800 vs 7000 mg) vs combination bamlanivimab and etesevimab v

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial | Colorectal Cancer | JAMA - Vimarsana News

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial | Colorectal Cancer | JAMA

This randomized clinical trial assesses the effect of adding panitumumab vs bevacizumab to standard first-line chemotherapy on overall survival among patients w